Lawrence Otto Klein, CRISPR Therapeutics AG's CBO & COO, recently acquired 16,334 shares of the company. The buys took place at $14.43 per share, on January 15, 2021. Klein now owns 37,550 shares of the company. Klein operates out of Cambridge, MA. Some additional info was provided as follows:
This amended Form 4 is being filed to correct the number of shares acquired on January 15, 2021.
The original Form 4 filed on January 20, 2021 inadvertently included the wrong amount of shares beneficially owned after each transaction. This amended Form 4 is being filed to correct the number of shares beneficially owned following the transactions on January 15, 2021.
The above information was disclosed in a filing to the SEC. To see the f iling, click here.
To receive a free e-mail notification whenever CRISPR Therapeutics AG makes a similar move, sign up!
Other recent filings from the company include the following:
CRISPR Therapeutics AG's Chief Executive Officer just cashed-in 30,000 options - June 17, 2021
CRISPR Therapeutics AG director just disposed of 10,000 shares - June 15, 2021
CRISPR Therapeutics AG director was just granted 10,000 options - June 14, 2021
Amendments to Articles of Incorporation or - June 14, 2021
Statement of changes in beneficial ownership of securities - June 14, 2021